APO Research
Talk to an analyst

APO RESEARCH · REPORT

Influenza (Flu) Antiviral Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Influenza (Flu) Antiviral Drugs Industry Growth and Trends Forecast to 2032

2 January 2026122 pages

Choose your research edition.

Industry ResearchInfluenza (Flu) Antiviral Drugs Industry Research Report 2026149 pages · $2,950 USDIndustry Growth & TrendsGlobal Influenza (Flu) Antiviral Drugs Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Influenza (Flu) Antiviral Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Influenza (Flu) Antiviral Drugs Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Influenza (Flu) Antiviral Drugs Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

The global Influenza (Flu) Antiviral Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Influenza (Flu) Antiviral Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Influenza (Flu) Antiviral Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Influenza (Flu) Antiviral Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Influenza (Flu) Antiviral Drugs include Allergan, Aurobindo Pharma, Boehringer Ingelheim, Bristol-Myers Squibb, Bristol-Myers-Squibb, Cipla, F. Hoffmann-La Roche, Gilead Sciences and GlaxoSmithKline (GSK), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Influenza (Flu) Antiviral Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Influenza (Flu) Antiviral Drugs market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Influenza (Flu) Antiviral Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Influenza (Flu) Antiviral Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Influenza (Flu) Antiviral Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Influenza (Flu) Antiviral Drugs Market by Company

Allergan

Aurobindo Pharma

Boehringer Ingelheim

Bristol-Myers Squibb

Bristol-Myers-Squibb

Cipla

F. Hoffmann-La Roche

Gilead Sciences

GlaxoSmithKline (GSK)

Merck & Co. (MSD)

Novo Nordisk

Teva Pharmaceutical Industries

AstraZeneca

AbbVie

Amgen

Bayer

Pfizer

Eli Lilly

Roche

Mylan

Novartis

Johnson & Johnson

Sanofi

Teva

Takeda

Influenza (Flu) Antiviral Drugs Segment by Type

Neuraminidase Inhibitors

Reverse Transcriptase Inhibitors

Broad-spectrum Antiviral Drugs

Protein Inhibitors

Penetration and Dehulling Inhibitors

DNA Polymerase Inhibitors

Influenza (Flu) Antiviral Drugs Segment by Application

Clinic

Hospital

Household

Others

Influenza (Flu) Antiviral Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Influenza (Flu) Antiviral Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Influenza (Flu) Antiviral Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Influenza (Flu) Antiviral Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Influenza (Flu) Antiviral Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Influenza (Flu) Antiviral Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Neuraminidase Inhibitors Table 2. Major Company of Reverse Transcriptase Inhibitors Table 3. Major Company of Broad-spectrum Antiviral Drugs Table 4. Major Company of Protein Inhibitors Table 5. Major Company of Penetration and Dehulling Inhibitors Table 6. Major Company of DNA Polymerase Inhibitors Table 7. Global Influenza (Flu) Antiviral Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 8. Global Influenza (Flu) Antiviral Drugs Sales by Type (2021-2026) & (K Units) Table 9. Global Influenza (Flu) Antiviral Drugs Sales Market Share in Volume by Type (2021-2026) Table 10. Global Influenza (Flu) Antiviral Drugs Sales by Type (2021-2026) & (US$ Million) Table 11. Global Influenza (Flu) Antiviral Drugs Sales Market Share in Value by Type (2021-2026) Table 12. Global Influenza (Flu) Antiviral Drugs Price by Type (2021-2026) & (US$/Unit) Table 13. Global Influenza (Flu) Antiviral Drugs Sales by Type (2027-2032) & (K Units) Table 14. Global Influenza (Flu) Antiviral Drugs Sales Market Share in Volume by Type (2027-2032) Table 15. Global Influenza (Flu) Antiviral Drugs Sales by Type (2027-2032) & (US$ Million) Table 16. Global Influenza (Flu) Antiviral Drugs Sales Market Share in Value by Type (2027-2032) Table 17. Global Influenza (Flu) Antiviral Drugs Price by Type (2027-2032) & (US$/Unit) Table 18. North America Influenza (Flu) Antiviral Drugs Sales by Type (2021-2026) & (K Units) Table 19. North America Influenza (Flu) Antiviral Drugs Sales by Type (2021-2026) & (US$ Million) Table 20. Europe Influenza (Flu) Antiviral Drugs Sales by Type (2021-2026) & (K Units) Table 21. Europe Influenza (Flu) Antiviral Drugs Sales by Type (2021-2026) & (US$ Million) Table 22. Asia-Pacific Influenza (Flu) Antiviral Drugs Sales by Type (2021-2026) & (K Units) Table 23. Asia-Pacific Influenza (Flu) Antiviral Drugs Sales by Type (2021-2026) & (US$ Million) Table 24. Latin America Influenza (Flu) Antiviral Drugs Sales by Type (2021-2026) & (K Units) Table 25. Latin America Influenza (Flu) Antiviral Drugs Sales by Type (2021-2026) & (US$ Million) Table 26. Middle East and Africa Influenza (Flu) Antiviral Drugs Sales by Type (2021-2026) & (K Units) Table 27. Middle East and Africa Influenza (Flu) Antiviral Drugs Sales by Type (2021-2026) & (US$ Million) Table 28. Influenza (Flu) Antiviral Drugs Industry Trends Table 29. Influenza (Flu) Antiviral Drugs Industry Drivers Table 30. Influenza (Flu) Antiviral Drugs Industry Opportunities and Challenges Table 31. Influenza (Flu) Antiviral Drugs Industry Restraints Table 32. Global Influenza (Flu) Antiviral Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 33. Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Company (2021-2026) Table 34. Global Influenza (Flu) Antiviral Drugs Sales by Company (2021-2026) & (K Units) Table 35. Global Influenza (Flu) Antiviral Drugs Sales Share by Company (2021-2026) Table 36. Global Influenza (Flu) Antiviral Drugs Market Price by Company (2021-2026) & (US$/Unit) Table 37. Global Influenza (Flu) Antiviral Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 38. Global Influenza (Flu) Antiviral Drugs Major Company Production Sites and Headquarters Table 39. Global Influenza (Flu) Antiviral Drugs Company, Product Type & Application Table 40. Global Influenza (Flu) Antiviral Drugs Company Establishment Date Table 41. Global Company Market Concentration Ratio (CR5 and HHI) Table 42. Global Influenza (Flu) Antiviral Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 43. Global Influenza (Flu) Antiviral Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global Influenza (Flu) Antiviral Drugs Sales by Region (2021-2026) & (K Units) Table 45. Global Influenza (Flu) Antiviral Drugs Sales Market Share in Volume by Region (2021-2026) Table 46. Global Influenza (Flu) Antiviral Drugs Sales by Region (2021-2026) & (US$ Million) Table 47. Global Influenza (Flu) Antiviral Drugs Sales Market Share in Value by Region (2021-2026) Table 48. Global Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 49. Global Influenza (Flu) Antiviral Drugs Sales by Region (2027-2032) & (K Units) Table 50. Global Influenza (Flu) Antiviral Drugs Sales Market Share in Volume by Region (2027-2032) Table 51. Global Influenza (Flu) Antiviral Drugs Sales by Region (2027-2032) & (US$ Million) Table 52. Global Influenza (Flu) Antiviral Drugs Sales Market Share in Value by Region (2027-2032) Table 53. Global Influenza (Flu) Antiviral Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 54. Global Influenza (Flu) Antiviral Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 55. Global Influenza (Flu) Antiviral Drugs Sales by Application (2021-2026) & (K Units) Table 56. Global Influenza (Flu) Antiviral Drugs Sales Market Share in Volume by Application (2021-2026) Table 57. Global Influenza (Flu) Antiviral Drugs Sales by Application (2021-2026) & (US$ Million) Table 58. Global Influenza (Flu) Antiviral Drugs Sales Market Share in Value by Application (2021-2026) Table 59. Global Influenza (Flu) Antiviral Drugs Price by Application (2021-2026) & (US$/Unit) Table 60. Global Influenza (Flu) Antiviral Drugs Sales by Application (2027-2032) & (K Units) Table 61. Global Influenza (Flu) Antiviral Drugs Sales Market Share in Volume by Application (2027-2032) Table 62. Global Influenza (Flu) Antiviral Drugs Sales by Application (2027-2032) & (US$ Million) Table 63. Global Influenza (Flu) Antiviral Drugs Sales Market Share in Value by Application (2027-2032) Table 64. Global Influenza (Flu) Antiviral Drugs Price by Application (2027-2032) & (US$/Unit) Table 65. North America Influenza (Flu) Antiviral Drugs Sales by Application (2021-2026) & (K Units) Table 66. North America Influenza (Flu) Antiviral Drugs Sales by Application (2021-2026) & (US$ Million) Table 67. Europe Influenza (Flu) Antiviral Drugs Sales by Application (2021-2026) & (K Units) Table 68. Europe Influenza (Flu) Antiviral Drugs Sales by Application (2021-2026) & (US$ Million) Table 69. Asia-Pacific Influenza (Flu) Antiviral Drugs Sales by Application (2021-2026) & (K Units) Table 70. Asia-Pacific Influenza (Flu) Antiviral Drugs Sales by Application (2021-2026) & (US$ Million) Table 71. Latin America Influenza (Flu) Antiviral Drugs Sales by Application (2021-2026) & (K Units) Table 72. Latin America Influenza (Flu) Antiviral Drugs Sales by Application (2021-2026) & (US$ Million) Table 73. Middle East and Africa Influenza (Flu) Antiviral Drugs Sales by Application (2021-2026) & (K Units) Table 74. Middle East and Africa Influenza (Flu) Antiviral Drugs Sales by Application (2021-2026) & (US$ Million) Table 75. Allergan Company Information Table 76. Allergan Business Overview Table 77. Allergan Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Allergan Influenza (Flu) Antiviral Drugs Product Portfolio Table 79. Allergan Recent Development Table 80. Aurobindo Pharma Company Information Table 81. Aurobindo Pharma Business Overview Table 82. Aurobindo Pharma Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Aurobindo Pharma Influenza (Flu) Antiviral Drugs Product Portfolio Table 84. Aurobindo Pharma Recent Development Table 85. Boehringer Ingelheim Company Information Table 86. Boehringer Ingelheim Business Overview Table 87. Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Product Portfolio Table 89. Boehringer Ingelheim Recent Development Table 90. Bristol-Myers Squibb Company Information Table 91. Bristol-Myers Squibb Business Overview Table 92. Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Product Portfolio Table 94. Bristol-Myers Squibb Recent Development Table 95. Bristol-Myers-Squibb Company Information Table 96. Bristol-Myers-Squibb Business Overview Table 97. Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Product Portfolio Table 99. Bristol-Myers-Squibb Recent Development Table 100. Cipla Company Information Table 101. Cipla Business Overview Table 102. Cipla Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Cipla Influenza (Flu) Antiviral Drugs Product Portfolio Table 104. Cipla Recent Development Table 105. F. Hoffmann-La Roche Company Information Table 106. F. Hoffmann-La Roche Business Overview Table 107. F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Product Portfolio Table 109. F. Hoffmann-La Roche Recent Development Table 110. Gilead Sciences Company Information Table 111. Gilead Sciences Business Overview Table 112. Gilead Sciences Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Gilead Sciences Influenza (Flu) Antiviral Drugs Product Portfolio Table 114. Gilead Sciences Recent Development Table 115. GlaxoSmithKline (GSK) Company Information Table 116. GlaxoSmithKline (GSK) Business Overview Table 117. GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Product Portfolio Table 119. GlaxoSmithKline (GSK) Recent Development Table 120. Merck & Co. (MSD) Company Information Table 121. Merck & Co. (MSD) Business Overview Table 122. Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Product Portfolio Table 124. Merck & Co. (MSD) Recent Development Table 125. Novo Nordisk Company Information Table 126. Novo Nordisk Business Overview Table 127. Novo Nordisk Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Novo Nordisk Influenza (Flu) Antiviral Drugs Product Portfolio Table 129. Novo Nordisk Recent Development Table 130. Teva Pharmaceutical Industries Company Information Table 131. Teva Pharmaceutical Industries Business Overview Table 132. Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Product Portfolio Table 134. Teva Pharmaceutical Industries Recent Development Table 135. AstraZeneca Company Information Table 136. AstraZeneca Business Overview Table 137. AstraZeneca Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. AstraZeneca Influenza (Flu) Antiviral Drugs Product Portfolio Table 139. AstraZeneca Recent Development Table 140. AbbVie Company Information Table 141. AbbVie Business Overview Table 142. AbbVie Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. AbbVie Influenza (Flu) Antiviral Drugs Product Portfolio Table 144. AbbVie Recent Development Table 145. Amgen Company Information Table 146. Amgen Business Overview Table 147. Amgen Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 148. Amgen Influenza (Flu) Antiviral Drugs Product Portfolio Table 149. Amgen Recent Development Table 150. Bayer Company Information Table 151. Bayer Business Overview Table 152. Bayer Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 153. Bayer Influenza (Flu) Antiviral Drugs Product Portfolio Table 154. Bayer Recent Development Table 155. Pfizer Company Information Table 156. Pfizer Business Overview Table 157. Pfizer Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 158. Pfizer Influenza (Flu) Antiviral Drugs Product Portfolio Table 159. Pfizer Recent Development Table 160. Eli Lilly Company Information Table 161. Eli Lilly Business Overview Table 162. Eli Lilly Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 163. Eli Lilly Influenza (Flu) Antiviral Drugs Product Portfolio Table 164. Eli Lilly Recent Development Table 165. Roche Company Information Table 166. Roche Business Overview Table 167. Roche Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 168. Roche Influenza (Flu) Antiviral Drugs Product Portfolio Table 169. Roche Recent Development Table 170. Mylan Company Information Table 171. Mylan Business Overview Table 172. Mylan Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 173. Mylan Influenza (Flu) Antiviral Drugs Product Portfolio Table 174. Mylan Recent Development Table 175. Novartis Company Information Table 176. Novartis Business Overview Table 177. Novartis Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 178. Novartis Influenza (Flu) Antiviral Drugs Product Portfolio Table 179. Novartis Recent Development Table 180. Johnson & Johnson Company Information Table 181. Johnson & Johnson Business Overview Table 182. Johnson & Johnson Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 183. Johnson & Johnson Influenza (Flu) Antiviral Drugs Product Portfolio Table 184. Johnson & Johnson Recent Development Table 185. Sanofi Company Information Table 186. Sanofi Business Overview Table 187. Sanofi Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 188. Sanofi Influenza (Flu) Antiviral Drugs Product Portfolio Table 189. Sanofi Recent Development Table 190. Teva Company Information Table 191. Teva Business Overview Table 192. Teva Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 193. Teva Influenza (Flu) Antiviral Drugs Product Portfolio Table 194. Teva Recent Development Table 195. Takeda Company Information Table 196. Takeda Business Overview Table 197. Takeda Influenza (Flu) Antiviral Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 198. Takeda Influenza (Flu) Antiviral Drugs Product Portfolio Table 199. Takeda Recent Development Table 200. North America Influenza (Flu) Antiviral Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 201. North America Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026) & (K Units) Table 202. North America Influenza (Flu) Antiviral Drugs Sales Market Share by Country (2021-2026) Table 203. North America Influenza (Flu) Antiviral Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 204. North America Influenza (Flu) Antiviral Drugs Sales Market Share Forecast by Country (2027-2032) Table 205. North America Influenza (Flu) Antiviral Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 206. North America Influenza (Flu) Antiviral Drugs Market Size by Country (2021-2026) & (US$ Million) Table 207. North America Influenza (Flu) Antiviral Drugs Market Share by Country (2021-2026) Table 208. North America Influenza (Flu) Antiviral Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 209. North America Influenza (Flu) Antiviral Drugs Market Share Forecast by Country (2027-2032) Table 210. Europe Influenza (Flu) Antiviral Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 211. Europe Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026) & (K Units) Table 212. Europe Influenza (Flu) Antiviral Drugs Sales Market Share by Country (2021-2026) Table 213. Europe Influenza (Flu) Antiviral Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 214. Europe Influenza (Flu) Antiviral Drugs Sales Market Share Forecast by Country (2027-2032) Table 215. Europe Influenza (Flu) Antiviral Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 216. Europe Influenza (Flu) Antiviral Drugs Market Size by Country (2021-2026) & (US$ Million) Table 217. Europe Influenza (Flu) Antiviral Drugs Market Share by Country (2021-2026) Table 218. Europe Influenza (Flu) Antiviral Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 219. Europe Influenza (Flu) Antiviral Drugs Market Share Forecast by Country (2027-2032) Table 220. Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 221. Asia-Pacific Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026) & (K Units) Table 222. Asia-Pacific Influenza (Flu) Antiviral Drugs Sales Market Share by Country (2021-2026) Table 223. Asia-Pacific Influenza (Flu) Antiviral Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 224. Asia-Pacific Influenza (Flu) Antiviral Drugs Sales Market Share Forecast by Country (2027-2032) Table 225. Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 226. Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Country (2021-2026) & (US$ Million) Table 227. Asia-Pacific Influenza (Flu) Antiviral Drugs Market Share by Country (2021-2026) Table 228. Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 229. Asia-Pacific Influenza (Flu) Antiviral Drugs Market Share Forecast by Country (2027-2032) Table 230. Latin America Influenza (Flu) Antiviral Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 231. Latin America Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026) & (K Units) Table 232. Latin America Influenza (Flu) Antiviral Drugs Sales Market Share by Country (2021-2026) Table 233. Latin America Influenza (Flu) Antiviral Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 234. Latin America Influenza (Flu) Antiviral Drugs Sales Market Share Forecast by Country (2027-2032) Table 235. Latin America Influenza (Flu) Antiviral Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 236. Latin America Influenza (Flu) Antiviral Drugs Market Size by Country (2021-2026) & (US$ Million) Table 237. Latin America Influenza (Flu) Antiviral Drugs Market Share by Country (2021-2026) Table 238. Latin America Influenza (Flu) Antiviral Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 239. Latin America Influenza (Flu) Antiviral Drugs Market Share Forecast by Country (2027-2032) Table 240. Middle East and Africa Influenza (Flu) Antiviral Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 241. Middle East and Africa Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026) & (K Units) Table 242. Middle East and Africa Influenza (Flu) Antiviral Drugs Sales Market Share by Country (2021-2026) Table 243. Middle East and Africa Influenza (Flu) Antiviral Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 244. Middle East and Africa Influenza (Flu) Antiviral Drugs Sales Market Share Forecast by Country (2027-2032) Table 245. Middle East and Africa Influenza (Flu) Antiviral Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 246. Middle East and Africa Influenza (Flu) Antiviral Drugs Market Size by Country (2021-2026) & (US$ Million) Table 247. Middle East and Africa Influenza (Flu) Antiviral Drugs Market Share by Country (2021-2026) Table 248. Middle East and Africa Influenza (Flu) Antiviral Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 249. Middle East and Africa Influenza (Flu) Antiviral Drugs Market Share Forecast by Country (2027-2032) Table 250. Key Raw Materials Table 251. Raw Materials Key Suppliers Table 252. Influenza (Flu) Antiviral Drugs Distributors List Table 253. Influenza (Flu) Antiviral Drugs Customers List Table 254. Research Programs/Design for This Report Table 255. Authors List of This Report Table 256. Secondary Sources Table 257. Primary Sources List of Figures Figure 1. Influenza (Flu) Antiviral Drugs Image Figure 2. Global Influenza (Flu) Antiviral Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Influenza (Flu) Antiviral Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Influenza (Flu) Antiviral Drugs Sales (2021-2032) & (K Units) Figure 5. Neuraminidase Inhibitors Image Figure 6. Global Neuraminidase Inhibitors Sales YoY Growth (2021-2032) & (K Units) Figure 7. Reverse Transcriptase Inhibitors Image Figure 8. Global Reverse Transcriptase Inhibitors Sales YoY Growth (2021-2032) & (K Units) Figure 9. Broad-spectrum Antiviral Drugs Image Figure 10. Global Broad-spectrum Antiviral Drugs Sales YoY Growth (2021-2032) & (K Units) Figure 11. Protein Inhibitors Image Figure 12. Global Protein Inhibitors Sales YoY Growth (2021-2032) & (K Units) Figure 13. Penetration and Dehulling Inhibitors Image Figure 14. Global Penetration and Dehulling Inhibitors Sales YoY Growth (2021-2032) & (K Units) Figure 15. DNA Polymerase Inhibitors Image Figure 16. Global DNA Polymerase Inhibitors Sales YoY Growth (2021-2032) & (K Units) Figure 17. Global Influenza (Flu) Antiviral Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 18. Global Influenza (Flu) Antiviral Drugs Market Share by Type 2025 VS 2032 Figure 19. North America Influenza (Flu) Antiviral Drugs Sales Market Share in Volume by Type in 2025 Figure 20. North America Influenza (Flu) Antiviral Drugs Sales Market Share in Value by Type in 2025 Figure 21. Europe Influenza (Flu) Antiviral Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Europe Influenza (Flu) Antiviral Drugs Sales Market Share in Value by Type in 2025 Figure 23. Asia-Pacific Influenza (Flu) Antiviral Drugs Sales Market Share in Volume by Type in 2025 Figure 24. Asia-Pacific Influenza (Flu) Antiviral Drugs Sales Market Share in Value by Type in 2025 Figure 25. Latin America Influenza (Flu) Antiviral Drugs Sales Market Share in Volume by Type in 2025 Figure 26. Latin America Influenza (Flu) Antiviral Drugs Sales Market Share in Value by Type in 2025 Figure 27. Middle East and Africa Influenza (Flu) Antiviral Drugs Sales Market Share in Volume by Type in 2025 Figure 28. Middle East and Africa Influenza (Flu) Antiviral Drugs Sales Market Share in Value by Type in 2025 Figure 29. Global Top 5 and 10 Influenza (Flu) Antiviral Drugs Players Market Share by Revenue in 2025 Figure 30. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Clinic Image Figure 32. Global Clinic Sales YoY Growth (2021-2032) & (K Units) Figure 33. Hospital Image Figure 34. Global Hospital Sales YoY Growth (2021-2032) & (K Units) Figure 35. Household Image Figure 36. Global Household Sales YoY Growth (2021-2032) & (K Units) Figure 37. Others Image Figure 38. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 39. Global Influenza (Flu) Antiviral Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 40. Global Influenza (Flu) Antiviral Drugs Market Share by Application 2025 VS 2032 Figure 41. North America Influenza (Flu) Antiviral Drugs Sales Market Share in Volume by Application in 2025 Figure 42. North America Influenza (Flu) Antiviral Drugs Sales Market Share in Value by Application in 2025 Figure 43. Europe Influenza (Flu) Antiviral Drugs Sales Market Share in Volume by Application in 2025 Figure 44. Europe Influenza (Flu) Antiviral Drugs Sales Market Share in Value by Application in 2025 Figure 45. Asia-Pacific Influenza (Flu) Antiviral Drugs Sales Market Share in Volume by Application in 2025 Figure 46. Asia-Pacific Influenza (Flu) Antiviral Drugs Sales Market Share in Value by Application in 2025 Figure 47. Latin America Influenza (Flu) Antiviral Drugs Sales Market Share in Volume by Application in 2025 Figure 48. Latin America Influenza (Flu) Antiviral Drugs Sales Market Share in Value by Application in 2025 Figure 49. Middle East and Africa Influenza (Flu) Antiviral Drugs Sales Market Share in Volume by Application in 2025 Figure 50. Middle East and Africa Influenza (Flu) Antiviral Drugs Sales Market Share in Value by Application in 2025 Figure 51. North America Influenza (Flu) Antiviral Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. North America Influenza (Flu) Antiviral Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. North America Influenza (Flu) Antiviral Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. North America Influenza (Flu) Antiviral Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Influenza (Flu) Antiviral Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Europe Influenza (Flu) Antiviral Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe Influenza (Flu) Antiviral Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Europe Influenza (Flu) Antiviral Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Influenza (Flu) Antiviral Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Asia-Pacific Influenza (Flu) Antiviral Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Asia-Pacific Influenza (Flu) Antiviral Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Influenza (Flu) Antiviral Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Latin America Influenza (Flu) Antiviral Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America Influenza (Flu) Antiviral Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Latin America Influenza (Flu) Antiviral Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Influenza (Flu) Antiviral Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 68. Middle East and Africa Influenza (Flu) Antiviral Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa Influenza (Flu) Antiviral Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 70. Middle East and Africa Influenza (Flu) Antiviral Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 71. Influenza (Flu) Antiviral Drugs Value Chain Figure 72. Key Raw Materials Price Figure 73. Manufacturing Cost Structure Figure 74. Influenza (Flu) Antiviral Drugs Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • Neuraminidase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Broad-spectrum Antiviral Drugs
  • Protein Inhibitors
  • Penetration and Dehulling Inhibitors
  • DNA Polymerase Inhibitors
Applications
  • Clinic
  • Hospital
  • Household
  • Others
Companies covered
  • Allergan
  • Aurobindo Pharma
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Bristol-Myers-Squibb
  • Cipla
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • GlaxoSmithKline (GSK)
  • Merck & Co. (MSD)
  • Novo Nordisk
  • Teva Pharmaceutical Industries
  • AstraZeneca
  • AbbVie
  • Amgen
  • Bayer
  • Pfizer
  • Eli Lilly
  • Roche
  • Mylan
  • Novartis
  • Johnson & Johnson
  • Sanofi
  • Teva
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Influenza (Flu) Antiviral Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Influenza (Flu) Antiviral Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Influenza (Flu) Antiviral Drugs Market by Type
  6. 1.3.1 Neuraminidase Inhibitors
  7. 1.3.2 Reverse Transcriptase Inhibitors
  8. 1.3.3 Broad-spectrum Antiviral Drugs
  9. 1.3.4 Protein Inhibitors
  10. 1.3.5 Penetration and Dehulling Inhibitors
  11. 1.3.6 DNA Polymerase Inhibitors
  12. 1.4 Global Influenza (Flu) Antiviral Drugs Market Size by Type
  13. 1.4.1 Global Influenza (Flu) Antiviral Drugs Market Size Overview by Type (2021-2032)
  14. 1.4.2 Global Influenza (Flu) Antiviral Drugs Historic Market Size Review by Type (2021-2026)
  15. 1.4.3 Global Influenza (Flu) Antiviral Drugs Forecasted Market Size by Type (2027-2032)
  16. 1.5 Key Regions Market Size by Type
  17. 1.5.1 North America Influenza (Flu) Antiviral Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.2 Europe Influenza (Flu) Antiviral Drugs Sales Breakdown by Type (2021-2026)
  19. 1.5.3 Asia-Pacific Influenza (Flu) Antiviral Drugs Sales Breakdown by Type (2021-2026)
  20. 1.5.4 South America Influenza (Flu) Antiviral Drugs Sales Breakdown by Type (2021-2026)
  21. 1.5.5 Middle East and Africa Influenza (Flu) Antiviral Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Influenza (Flu) Antiviral Drugs Industry Trends
  2. 2.2 Influenza (Flu) Antiviral Drugs Industry Drivers
  3. 2.3 Influenza (Flu) Antiviral Drugs Industry Opportunities and Challenges
  4. 2.4 Influenza (Flu) Antiviral Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Influenza (Flu) Antiviral Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Influenza (Flu) Antiviral Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Influenza (Flu) Antiviral Drugs Price (2021-2026)
  4. 3.4 Global Influenza (Flu) Antiviral Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Influenza (Flu) Antiviral Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Influenza (Flu) Antiviral Drugs Company, Product Type & Application
  7. 3.7 Global Influenza (Flu) Antiviral Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Influenza (Flu) Antiviral Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Influenza (Flu) Antiviral Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Influenza (Flu) Antiviral Drugs Tier 1, Tier 2, and Tier 3
4 Influenza (Flu) Antiviral Drugs Regional Status and Outlook
  1. 4.1 Global Influenza (Flu) Antiviral Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Influenza (Flu) Antiviral Drugs Historic Market Size by Region
  3. 4.2.1 Global Influenza (Flu) Antiviral Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Influenza (Flu) Antiviral Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Influenza (Flu) Antiviral Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Influenza (Flu) Antiviral Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Influenza (Flu) Antiviral Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Influenza (Flu) Antiviral Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Influenza (Flu) Antiviral Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Influenza (Flu) Antiviral Drugs by Application
  1. 5.1 Influenza (Flu) Antiviral Drugs Market by Application
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Household
  5. 5.1.4 Others
  6. 5.2 Global Influenza (Flu) Antiviral Drugs Market Size by Application
  7. 5.2.1 Global Influenza (Flu) Antiviral Drugs Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Influenza (Flu) Antiviral Drugs Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Influenza (Flu) Antiviral Drugs Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Influenza (Flu) Antiviral Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Influenza (Flu) Antiviral Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Influenza (Flu) Antiviral Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Influenza (Flu) Antiviral Drugs Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Influenza (Flu) Antiviral Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Allergan
  2. 6.1.1 Allergan Company Information
  3. 6.1.2 Allergan Business Overview
  4. 6.1.3 Allergan Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Allergan Influenza (Flu) Antiviral Drugs Product Portfolio
  6. 6.1.5 Allergan Recent Developments
  7. 6.2 Aurobindo Pharma
  8. 6.2.1 Aurobindo Pharma Company Information
  9. 6.2.2 Aurobindo Pharma Business Overview
  10. 6.2.3 Aurobindo Pharma Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Aurobindo Pharma Influenza (Flu) Antiviral Drugs Product Portfolio
  12. 6.2.5 Aurobindo Pharma Recent Developments
  13. 6.3 Boehringer Ingelheim
  14. 6.3.1 Boehringer Ingelheim Company Information
  15. 6.3.2 Boehringer Ingelheim Business Overview
  16. 6.3.3 Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Product Portfolio
  18. 6.3.5 Boehringer Ingelheim Recent Developments
  19. 6.4 Bristol-Myers Squibb
  20. 6.4.1 Bristol-Myers Squibb Company Information
  21. 6.4.2 Bristol-Myers Squibb Business Overview
  22. 6.4.3 Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Product Portfolio
  24. 6.4.5 Bristol-Myers Squibb Recent Developments
  25. 6.5 Bristol-Myers-Squibb
  26. 6.5.1 Bristol-Myers-Squibb Company Information
  27. 6.5.2 Bristol-Myers-Squibb Business Overview
  28. 6.5.3 Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Bristol-Myers-Squibb Influenza (Flu) Antiviral Drugs Product Portfolio
  30. 6.5.5 Bristol-Myers-Squibb Recent Developments
  31. 6.6 Cipla
  32. 6.6.1 Cipla Company Information
  33. 6.6.2 Cipla Business Overview
  34. 6.6.3 Cipla Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Cipla Influenza (Flu) Antiviral Drugs Product Portfolio
  36. 6.6.5 Cipla Recent Developments
  37. 6.7 F. Hoffmann-La Roche
  38. 6.7.1 F. Hoffmann-La Roche Company Information
  39. 6.7.2 F. Hoffmann-La Roche Business Overview
  40. 6.7.3 F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 F. Hoffmann-La Roche Influenza (Flu) Antiviral Drugs Product Portfolio
  42. 6.7.5 F. Hoffmann-La Roche Recent Developments
  43. 6.8 Gilead Sciences
  44. 6.8.1 Gilead Sciences Company Information
  45. 6.8.2 Gilead Sciences Business Overview
  46. 6.8.3 Gilead Sciences Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Gilead Sciences Influenza (Flu) Antiviral Drugs Product Portfolio
  48. 6.8.5 Gilead Sciences Recent Developments
  49. 6.9 GlaxoSmithKline (GSK)
  50. 6.9.1 GlaxoSmithKline (GSK) Company Information
  51. 6.9.2 GlaxoSmithKline (GSK) Business Overview
  52. 6.9.3 GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Product Portfolio
  54. 6.9.5 GlaxoSmithKline (GSK) Recent Developments
  55. 6.10 Merck & Co. (MSD)
  56. 6.10.1 Merck & Co. (MSD) Company Information
  57. 6.10.2 Merck & Co. (MSD) Business Overview
  58. 6.10.3 Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Product Portfolio
  60. 6.10.5 Merck & Co. (MSD) Recent Developments
  61. 6.11 Novo Nordisk
  62. 6.11.1 Novo Nordisk Company Information
  63. 6.11.2 Novo Nordisk Business Overview
  64. 6.11.3 Novo Nordisk Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Novo Nordisk Influenza (Flu) Antiviral Drugs Product Portfolio
  66. 6.11.5 Novo Nordisk Recent Developments
  67. 6.12 Teva Pharmaceutical Industries
  68. 6.12.1 Teva Pharmaceutical Industries Company Information
  69. 6.12.2 Teva Pharmaceutical Industries Business Overview
  70. 6.12.3 Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Teva Pharmaceutical Industries Influenza (Flu) Antiviral Drugs Product Portfolio
  72. 6.12.5 Teva Pharmaceutical Industries Recent Developments
  73. 6.13 AstraZeneca
  74. 6.13.1 AstraZeneca Company Information
  75. 6.13.2 AstraZeneca Business Overview
  76. 6.13.3 AstraZeneca Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 AstraZeneca Influenza (Flu) Antiviral Drugs Product Portfolio
  78. 6.13.5 AstraZeneca Recent Developments
  79. 6.14 AbbVie
  80. 6.14.1 AbbVie Company Information
  81. 6.14.2 AbbVie Business Overview
  82. 6.14.3 AbbVie Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 AbbVie Influenza (Flu) Antiviral Drugs Product Portfolio
  84. 6.14.5 AbbVie Recent Developments
  85. 6.15 Amgen
  86. 6.15.1 Amgen Company Information
  87. 6.15.2 Amgen Business Overview
  88. 6.15.3 Amgen Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Amgen Influenza (Flu) Antiviral Drugs Product Portfolio
  90. 6.15.5 Amgen Recent Developments
  91. 6.16 Bayer
  92. 6.16.1 Bayer Company Information
  93. 6.16.2 Bayer Business Overview
  94. 6.16.3 Bayer Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Bayer Influenza (Flu) Antiviral Drugs Product Portfolio
  96. 6.16.5 Bayer Recent Developments
  97. 6.17 Pfizer
  98. 6.17.1 Pfizer Company Information
  99. 6.17.2 Pfizer Business Overview
  100. 6.17.3 Pfizer Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Pfizer Influenza (Flu) Antiviral Drugs Product Portfolio
  102. 6.17.5 Pfizer Recent Developments
  103. 6.18 Eli Lilly
  104. 6.18.1 Eli Lilly Company Information
  105. 6.18.2 Eli Lilly Business Overview
  106. 6.18.3 Eli Lilly Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Eli Lilly Influenza (Flu) Antiviral Drugs Product Portfolio
  108. 6.18.5 Eli Lilly Recent Developments
  109. 6.19 Roche
  110. 6.19.1 Roche Company Information
  111. 6.19.2 Roche Business Overview
  112. 6.19.3 Roche Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  113. 6.19.4 Roche Influenza (Flu) Antiviral Drugs Product Portfolio
  114. 6.19.5 Roche Recent Developments
  115. 6.20 Mylan
  116. 6.20.1 Mylan Company Information
  117. 6.20.2 Mylan Business Overview
  118. 6.20.3 Mylan Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  119. 6.20.4 Mylan Influenza (Flu) Antiviral Drugs Product Portfolio
  120. 6.20.5 Mylan Recent Developments
  121. 6.21 Novartis
  122. 6.21.1 Novartis Company Information
  123. 6.21.2 Novartis Business Overview
  124. 6.21.3 Novartis Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  125. 6.21.4 Novartis Influenza (Flu) Antiviral Drugs Product Portfolio
  126. 6.21.5 Novartis Recent Developments
  127. 6.22 Johnson & Johnson
  128. 6.22.1 Johnson & Johnson Company Information
  129. 6.22.2 Johnson & Johnson Business Overview
  130. 6.22.3 Johnson & Johnson Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  131. 6.22.4 Johnson & Johnson Influenza (Flu) Antiviral Drugs Product Portfolio
  132. 6.22.5 Johnson & Johnson Recent Developments
  133. 6.23 Sanofi
  134. 6.23.1 Sanofi Company Information
  135. 6.23.2 Sanofi Business Overview
  136. 6.23.3 Sanofi Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  137. 6.23.4 Sanofi Influenza (Flu) Antiviral Drugs Product Portfolio
  138. 6.23.5 Sanofi Recent Developments
  139. 6.24 Teva
  140. 6.24.1 Teva Company Information
  141. 6.24.2 Teva Business Overview
  142. 6.24.3 Teva Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  143. 6.24.4 Teva Influenza (Flu) Antiviral Drugs Product Portfolio
  144. 6.24.5 Teva Recent Developments
  145. 6.25 Takeda
  146. 6.25.1 Takeda Company Information
  147. 6.25.2 Takeda Business Overview
  148. 6.25.3 Takeda Influenza (Flu) Antiviral Drugs Sales, Revenue and Gross Margin (2021-2026)
  149. 6.25.4 Takeda Influenza (Flu) Antiviral Drugs Product Portfolio
  150. 6.25.5 Takeda Recent Developments
7 North America by Country
  1. 7.1 North America Influenza (Flu) Antiviral Drugs Sales by Country
  2. 7.1.1 North America Influenza (Flu) Antiviral Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Influenza (Flu) Antiviral Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Influenza (Flu) Antiviral Drugs Market Size by Country
  6. 7.2.1 North America Influenza (Flu) Antiviral Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Influenza (Flu) Antiviral Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Influenza (Flu) Antiviral Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Influenza (Flu) Antiviral Drugs Sales by Country
  2. 8.1.1 Europe Influenza (Flu) Antiviral Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Influenza (Flu) Antiviral Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Influenza (Flu) Antiviral Drugs Market Size by Country
  6. 8.2.1 Europe Influenza (Flu) Antiviral Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Influenza (Flu) Antiviral Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Influenza (Flu) Antiviral Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Influenza (Flu) Antiviral Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Influenza (Flu) Antiviral Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Influenza (Flu) Antiviral Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Influenza (Flu) Antiviral Drugs Sales by Country
  2. 10.1.1 South America Influenza (Flu) Antiviral Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Influenza (Flu) Antiviral Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Influenza (Flu) Antiviral Drugs Market Size by Country
  6. 10.2.1 South America Influenza (Flu) Antiviral Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Influenza (Flu) Antiviral Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Influenza (Flu) Antiviral Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Influenza (Flu) Antiviral Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Influenza (Flu) Antiviral Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Influenza (Flu) Antiviral Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Influenza (Flu) Antiviral Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Influenza (Flu) Antiviral Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Influenza (Flu) Antiviral Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Influenza (Flu) Antiviral Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Influenza (Flu) Antiviral Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Influenza (Flu) Antiviral Drugs Value Chain Analysis
  2. 12.1.1 Influenza (Flu) Antiviral Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Influenza (Flu) Antiviral Drugs Production Mode & Process
  7. 12.2 Influenza (Flu) Antiviral Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Influenza (Flu) Antiviral Drugs Distributors
  10. 12.2.3 Influenza (Flu) Antiviral Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst